Zacks Investment Research cut shares of Innate Pharma (NASDAQ:IPHA) from a hold rating to a sell rating in a research note released on Saturday, Zacks.com reports.

According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company’s commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France. “

Several other equities analysts have also weighed in on the company. SVB Leerink cut their target price on Innate Pharma from $9.00 to $7.00 and set an outperform rating on the stock in a research note on Wednesday, September 9th. ValuEngine raised Innate Pharma from a hold rating to a buy rating in a research note on Wednesday, September 9th. Finally, Bryan, Garnier & Co lowered Innate Pharma from a buy rating to a neutral rating in a research note on Wednesday, September 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $7.00.

Innate Pharma stock opened at $4.35 on Friday. The business’s 50-day simple moving average is $5.97 and its 200 day simple moving average is $6.31. The stock has a market cap of $332.96 million and a price-to-earnings ratio of -12.79. Innate Pharma has a 12-month low of $3.30 and a 12-month high of $8.24. The company has a quick ratio of 1.95, a current ratio of 1.99 and a debt-to-equity ratio of 0.08.

About Innate Pharma

Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.

Featured Article: Hang Seng Index (HSI)

Get a free copy of the Zacks research report on Innate Pharma (IPHA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.